# Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

> **NCT03567720** · PHASE2 · UNKNOWN · sponsor: **OncoSec Medical Incorporated** · enrollment: 65 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** tavokinogene telseplasmid
- **BIOLOGICAL:** Pembrolizumab
- **DEVICE:** Immunopulse
- **DRUG:** nab paclitaxel
- **DRUG:** gemcitabine plus carboplatin

## Key facts

- **NCT ID:** NCT03567720
- **Lead sponsor:** OncoSec Medical Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-11
- **Primary completion:** 2024-04
- **Final completion:** 2024-09
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2023-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03567720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03567720, "Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03567720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*